| ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. |
globenewswire.com |
2025-05-13 17:00:00 |
Czytaj oryginał (ang.) |
| Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis |
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today |
globenewswire.com |
2025-05-06 20:30:00 |
Czytaj oryginał (ang.) |
| ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis |
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reiterated its confidence that the proposed combination with Alumis Inc. (Nasdaq: ALMS) is the best path forward and the most value-maximizing outcome for all ACELYRIN stockholders. Bruce Cozadd, Chair of the ACELYRIN Board of Directors and member of the independent transaction committee (the “Transaction Committee”), said, “The ACELYRIN Board and management team are confident that the proposed merger with Alumis represents the most value-maximizing path forward for our company's stockholders. |
globenewswire.com |
2025-05-01 17:30:00 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN Announce Amended Merger Agreement |
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis |
globenewswire.com |
2025-04-21 10:30:00 |
Czytaj oryginał (ang.) |
| ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i. |
businesswire.com |
2025-04-16 21:31:00 |
Czytaj oryginał (ang.) |
| ACELYRIN Adopts Limited-Duration Stockholder Rights Plan |
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (“Rights Plan”). |
globenewswire.com |
2025-03-13 09:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger |
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. |
globenewswire.com |
2025-03-04 11:01:00 |
Czytaj oryginał (ang.) |
| ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger |
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (Nasdaq: ALMS). |
globenewswire.com |
2025-03-04 11:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences |
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN's development programs or intellectual property. |
globenewswire.com |
2025-02-20 23:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i. |
businesswire.com |
2025-02-10 14:16:00 |
Czytaj oryginał (ang.) |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. |
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisition of the company by Alumis Inc. (NASDAQ: ALMS). |
prnewswire.com |
2025-02-07 17:22:00 |
Czytaj oryginał (ang.) |
| SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ACELYRIN, INC. (NASDAQ: SLRN) to Alumis Inc. for 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock is fair to ACELYRIN shareholders. Halper Sadeh encourages ACELYRIN shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The. |
businesswire.com |
2025-02-06 23:45:00 |
Czytaj oryginał (ang.) |
| $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Acelyrin, Inc. - SLRN |
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Acelyrin, Inc. (Nasdaq: SLRN ), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per share of common stock owned. |
prnewswire.com |
2025-02-06 22:16:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possible breaches of fiduciary duty and other violations of law in its transaction with Alumis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, ACELYRIN stockholders will receive only 0.4274 shares of Alumis common stock for each share of AC. |
businesswire.com |
2025-02-06 18:57:00 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 |
globenewswire.com |
2025-02-06 18:15:00 |
Czytaj oryginał (ang.) |
| Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. |
benzinga.com |
2025-01-07 10:42:11 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease |
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile |
globenewswire.com |
2025-01-06 18:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab |
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here. |
globenewswire.com |
2025-01-02 22:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis |
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance |
globenewswire.com |
2024-12-10 18:30:00 |
Czytaj oryginał (ang.) |
| Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript |
Acelyrin, Inc. (NASDAQ:SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the Acelyrin, Inc. Third Quarter 2024 Financial Results and Company Update Conference Call. |
seekingalpha.com |
2024-11-13 23:38:24 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights |
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 |
globenewswire.com |
2024-11-13 18:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 |
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates. |
globenewswire.com |
2024-11-06 18:00:00 |
Czytaj oryginał (ang.) |
| Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch |
Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events compared to other anti-IGF-1R therapies. |
seekingalpha.com |
2024-09-20 20:33:37 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 |
LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that positive results from the company's global Phase 3 clinical trial of izokibep in moderate-to-severe hidradenitis suppurativa (HS) patients will be shared as a late-breaking oral presentation at the 2024 European Academy of Dermatology and Venereology taking place September 25-28, 2024 in Amsterdam, Netherlands. Presentation details are as follows: |
globenewswire.com |
2024-09-19 11:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. to Participate in Upcoming Investor Conferences |
LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences: |
globenewswire.com |
2024-08-22 11:00:00 |
Czytaj oryginał (ang.) |
| Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep |
On Wednesday, Acelyrin Inc. SLRN confirmed that it was completing a 33% reduction in its workforce. |
benzinga.com |
2024-08-14 16:29:04 |
Czytaj oryginał (ang.) |
| Acelyrin, Inc. (SLRN) Q2 2024 Earnings Call Transcript |
Acelyrin, Inc. (NASDAQ:SLRN ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Tyler Marciniak - Vice President of Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Shep Mpofu - Chief Medical Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Conference Call Participants Derek Archila - Wells Fargo Tyler Van Buren - TD Cowen Yasmeen Rahimi - Piper Sandler Phoebe Tan - Jefferies Emily Bodnar - H.C. Wainwright Vikram Purohit - Morgan Stanley Samantha Semenkow - Citi Operator Good afternoon, and welcome to the ACELYRIN INC. |
seekingalpha.com |
2024-08-14 02:32:07 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 |
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update. |
globenewswire.com |
2024-08-06 20:30:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 |
Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients |
globenewswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones |
Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both trials now expected by end of third and fourth quarter of 2024, respectively |
globenewswire.com |
2024-05-09 12:01:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 |
LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to discuss its first quarter 2024 financial results and provide a corporate update. |
globenewswire.com |
2024-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights |
Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients |
globenewswire.com |
2024-03-28 18:05:00 |
Czytaj oryginał (ang.) |
| ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study |
ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains. |
zacks.com |
2024-03-21 14:16:05 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis |
Study met primary endpoint of ACR50 at 16 weeks versus placebo with high statistical significance and is expected to be the first of two registrational trials in psoriatic arthritis |
globenewswire.com |
2024-03-11 10:02:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients |
Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32 |
globenewswire.com |
2024-03-11 10:00:00 |
Czytaj oryginał (ang.) |
| ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications |
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies |
globenewswire.com |
2024-02-15 18:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline |
NEW YORK , Jan. 16, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Acelyrin, Inc. ("Acelyrin" or the "Company") (NASDAQ: SLRN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Acelyrin investors who were adversely affected by alleged securities fraud between May 4, 2023 and September 11, 2023. |
prnewswire.com |
2024-01-16 07:45:00 |
Czytaj oryginał (ang.) |